Sinopharm, a unit of the China National Pharmaceutical Group, and CanSinoBiologics Inc both have applied in China for the public use of their COVID-19 vaccines. Currently, China has two approved vaccines that were developed within the country, and has yet to approve any outside vaccines. The Sinopharm vaccine is said to have a 72.51% efficacy rate based on late-stage clinical trial data, while the CanSinoBio vaccine’s efficacy rate is 65.28% for preventing all symptomatic cases, and 90.07% for severe cases.
Read more here.
More on: News Regulatory